AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Volumetric Visual Fields at Different Distances in Presbyopic Patients Using Occupational (PC-133 and PC-200) and General-Purpose Progressive Addition Lenses

RecruitingNAAges 52 Years - 67 YearsAllUniversity of Seville
💬

In plain words

What the trial is, and whether it could suit you

This single-center, randomized, double-blind, crossover clinical trial aims to compare the volumetric visual fields provided by two occupational progressive addition lenses (OPLs) optimized for intermediate and near vision in presbyopic patients. The study evaluates Vimax PC 1.5 FWD 133 cm and Vimax PC 1.5 FWD 200 cm lenses and Vimax Fit FRM, all of them with plano distance power and a +2.00 D near addition, in order to determine differences in the extent of clear vision at multiple working distances. Participants will undergo a comprehensive optometric examination including medical and ocular history, visual acuity assessment, accommodative amplitude measurement, autorefraction, interpupillary distance measurement, ocular motility evaluation, confrontation visual fields, Amsler grid testing, and binocular vision assessment. Visual field measurements will then be performed using both st

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * • Spherical ametropia for distance vision ≤ ±4.00 D and astigmatic ametropia ≤ 1.00 D. * Decimal VA ≥ 0.8, either uncorrected (UCVA) or corrected (BCVA) with monofocal contact lenses. * Patients with a nasopupillary distance (NPD) of 31 mm, with a tolerance of ±2 mm in each eye Exclusion Criteria: * Astigmatism greater than ±1.00 D. * Patients wearing progressive contact lenses. * Patients who have undergone cataract surgery or have monofocal or multifocal intraocular lenses. * Anisometropia greater than 2.50 D. * Decimal distance visual acuity \< 0.8 (UCVA or BCVA) with monofocal contact lenses.
💊

What it tests

  • OPAL PC 133 assessment
  • OPAL PC 200 assessment
  • PAL assessment
📍

Where

1 site
Pharmacy School, University of Seville
Seville, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy